Filtered By:
Specialty: Infectious Diseases
Therapy: Corticosteroid Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 357 results found since Jan 2013.
Implementation and Outcomes of an Empiric Ivermectin Strongyloides Treatment Protocol for Patients Receiving High-Dose Corticosteroids for Severe COVID-19
Am J Trop Med Hyg. 2023 Jul 17;109(3):650-655. doi: 10.4269/ajtmh.23-0121. Print 2023 Sep 6.ABSTRACTStrongyloides stercoralis is a parasitic roundworm that is present worldwide and can cause lifelong, often asymptomatic, infection. Immunosuppression, particularly by corticosteroids, is a risk factor for hyperinfection syndrome and disseminated strongyloidiasis-severe disease states that can lead to septic shock and death. Our institution implemented a strongyloidiasis screening and empiric ivermectin treatment protocol for inpatients receiving high-dose corticosteroids for severe COVID-19. Among 487 COVID-19 admissions tre...
Source: Am J Trop Med Hyg - September 7, 2023 Category: Infectious Diseases Authors: Benjamin Swart Aileen Ahiskali Jack M Wolf Megan Shaughnessy Source Type: research
Tofacitinib versus oral prednisolone for induction of remission in moderately active ulcerative colitis (ORCHID): A prospective, open-label, randomized, pilot study
CONCLUSION: In patients with moderately active ulcerative colitis, there was no difference in the efficacy and safety of tofacitinib and oral prednisolone for induction of remission at 8 weeks.PMID:37656880 | DOI:10.1093/ecco-jcc/jjad153
Source: Herpes - September 1, 2023 Category: Infectious Diseases Authors: Arshdeep Singh Vandana Midha Kirandeep Kaur Ramit Mahajan Dharmatma Singh Ramandeep Kaur Aditya Kohli Avantika Chawla Kriti Sood Namita Bansal Ajit Sood Source Type: research
Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis: A Secondary Analysis
CONCLUSION AND RELEVANCE: The results of this post hoc analysis suggest that tralokinumab is well tolerated and efficacious in patients 65 years or older with moderate-to-severe AD.PMID:37610789 | DOI:10.1001/jamadermatol.2023.2626
Source: Herpes - August 23, 2023 Category: Infectious Diseases Authors: Joseph F Merola Daniel C Butler Thomas Mark Shannon Schneider Yestle Kim Katrina Abuabara Source Type: research
Acute Retinal Necrosis: Experience in a Reference Center in Santander - Colombia
CONCLUSIONS: Swift treatment is vital to ARN management. Our findings emphasize effective treatment strategies' role in visual prognosis.ABBREVIATIONS: ACV: Acyclovir; BCVA: Best Corrected Visual Acuity; CMV: Cytomegalovirus; EBV: Epstein Barr Virus; FTA-ABS: Fluorescent treponemal antibody absorption test; HSV 1-2: Herpes simplex virus 1-2; HIV: Human Immunodeficiency Virus; IV-ACV: Intravenous- Acyclovir; PCR: Polymerase Chain Reaction;Tg: Toxoplasma gondii; VZV: Varicella Zoster Virus; VCV: Valacyclovir; VDRL: Venereal disease research laboratory test.PMID:37582226 | DOI:10.1080/09273948.2023.2244076
Source: Herpes - August 15, 2023 Category: Infectious Diseases Authors: Carlos Mario Rangel Marcos Restrepo-Arango Germ án Mejía-Salgado Mar ía Alejandra Gómez-Rocha Maira G ómez Velasco Mar ía Fernanda García Juan Jos é Moreno Source Type: research
Rare case report: a 26-year-old man with Eales' disease
Conclusion: Despite the aggressive treatment with oral steroids, immunosuppressants, and anti-VEGF injections, there were many exacerbations, and remission was not achieved. As a result, aggressive neovascular glaucoma developed, which led to total blindness in the left eye and legal blindness in the right eye. Abbreviations: HLA = human leukocyte antigens, Anti-VEGF = vascular endothelial growth factor inhibitors, BCVA = best corrected visual acuity, FA = fundus angiography, HBsAg = hepatitis B surface antigen, Anti-HCV = hepatitis C antibodies, TPHA = Treponema Pallidum hemagglutination assay, PCR = polymerase chain reac...
Source: Herpes - July 31, 2023 Category: Infectious Diseases Authors: Sandra Bleidele Igors Solomatins A īda Macijevska Source Type: research
Baricitinib retention rate: 'real-life' data from a mono-centric cohort of patients affected by rheumatoid arthritis
CONCLUSION: Our data show a good baricitinib retention rate after 12 and 24 months of observation (75.1 and 69.3%, respectively). In our cohort, concomitant treatment with methotrexate did not influence treatment persistence while retention was reduced in patients undergoing a steroidal treatment and/or in multi-failure subjects.PMID:37448804 | PMC:PMC10336222 | DOI:10.3389/fmed.2023.1176613
Source: Herpes - July 14, 2023 Category: Infectious Diseases Authors: Caterina Baldi Virginia Berlengiero Paolo Falsetti Alessandra Cartocci Edoardo Conticini Roberto D'Alessandro Emilio D'Ignazio Marco Bardelli Marta Fabbroni Luca Cantarini Bruno Frediani Stefano Gentileschi Source Type: research
Glucocorticoid treatment in SLE is associated with infections, comorbidities, and mortality-a national cohort study
CONCLUSION: Results highlight the potential harm associated with even low OCS dose treatment in SLE and the need to judiciously use OCS at the lowest possible dose to maximize efficacy and minimize harm.PMID:37439705 | DOI:10.1093/rheumatology/kead348
Source: Herpes - July 13, 2023 Category: Infectious Diseases Authors: Martina Frodlund Andreas J önsen Lauren Remkus Gunilla Telg Fabian S öderdahl Dag Leonard Source Type: research
The Infectious Uveitis Treatment Algorithm Network (TITAN) Report 1-global current practice patterns for the management of Herpes Simplex Virus and Varicella Zoster Virus anterior uveitis
CONCLUSIONS: Consensus was reached on several aspects of diagnosis, choice of initial treatment, and treatment endpoints for HSV and VZV AU. Treatment duration and management of recurrences varied between experts.PMID:37419957 | DOI:10.1038/s41433-023-02630-9
Source: Herpes - July 7, 2023 Category: Infectious Diseases Authors: Zheng Xian Thng Ikhwanuliman Putera Ilaria Testi Kevin Chan Mark Westcott Soon-Phaik Chee Andrew D Dick John H Kempen Bahram Bodaghi Jennifer E Thorne Talin Barisani-Asenbauer Marc D de Smet Justine R Smith Peter McCluskey Rina La Distia Nora Douglas A Ja Source Type: research
Background factors predicting the occurrence of herpes zoster in atopic dermatitis patients treated with upadacitinib
J Dermatol. 2023 Jul 3. doi: 10.1111/1346-8138.16879. Online ahead of print.ABSTRACTUpadacitinib, an oral Janus kinase 1 inhibitor approved for treating atopic dermatitis (AD), can cause adverse events such as herpes zoster (HZ) and acne. We aimed to identify background factors predicting the occurrence of HZ and acne during upadacitinib treatment in patients with AD. From August 2021 to December 2022, 112 Japanese patients with moderate-to-severe AD (aged ≥12 years) were treated with upadacitinib 15 mg/day (78 patients) or 30 mg/day (34 patients) plus topical corticosteroids or delgocitinib limited to head and neck for ...
Source: Herpes - July 4, 2023 Category: Infectious Diseases Authors: Teppei Hagino Hidehisa Saeki Eita Fujimoto Naoko Kanda Source Type: research
